Dose-dependent effect of continuous erythropoietin receptor activator on cardiac autonomic nervous activity and cardiovascular events in patients treated with online hemodiafiltration

Authors

  • N. M. Stepanova SI “Institute of Nephrology NAMS of Ukraine”, Kyiv, Ukraine,
  • M. O. Kolesnyk SI “Institute of Nephrology NAMS of Ukraine”, Kyiv,
  • V. V. Novakivskyi Medical Center LLC “Fresenius Medical Care Ukraine”, Cherkasy, Ukraine,
  • O. M. Loboda SI “Institute of Nephrology NAMS of Ukraine”, Kyiv, Ukraine,
  • L. M. Snisar SI “Institute of Nephrology NAMS of Ukraine”, Kyiv, Ukraine,
  • I. M. Shifris SI “Institute of Nephrology NAMS of Ukraine”, Kyiv, Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2019.3.169112

Keywords:

renal replacement therapy, hemodiafiltration, anemia, heart rate, cardiovascular diseases

Abstract

 

The purpose of the work was to determine the effect of continuous erythropoietin receptor activator (CERA) on the autonomic regulation of cardiac activity and cardiovascular events in patients treated with online hemodiafiltration (HDF).

Materials and methods. A total of 105 stable chronic HDF patients were included in this prospective observational multicenter study. According to the CERA treatment, the patients were assigned to one of two groups: the 1st group (n = 73) received CERA for at least 6 months and the 2nd one (n = 32) consisted of HDF patients without CERA treatment for at least 6 months. The observational period was 3 years.

Results. It was determined that the patients receiving CERA had a more potent dose-dependent activity of the sympathetic autonomic nervous system. The higher the parasympathetic tone predominance, the lower CERA dose was. The odds ratio for developing nonfatal cardiovascular events was 37 times higher in case of CERA more than 125 μg/month (χ2 = 32.2; P ˂ 0.0001).

Conclusions. Thus, the results of this study have provided the preliminary evidence that the sympathetic ANS activity was greater in HDF patients receiving CERA and had a proportional dose-dependent nature. HDF patients with CERA treatment in a dose ≥125 µg/month had a significantly high risk of all cardiovascular events. Individual approach to low-dose CERA treatment in patients with CKD 5 and HDF could significantly reduce the risk of cardiovascular events.

References

Haensel, A., Mills, P. J., Nelesen, R. A., Ziegler, M. G., & Dimsdale, J. E. (2008). The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology, 33(10), 1305–1312. doi: 10.1016/j.psyneuen.2008.08.007

Schlaich, M. P. (2011). Sympathetic Activation in Chronic Kidney Disease. Hypertension. 57(4), 683–685. doi: 10.1161/HYPERTENSIONAHA.110.167189

Orihuela, O., de Jesús Ventura, M., Ávila-Díaz, M., Cisneros, A., Vicenté-Martínez, M., Furlong, M.-C., et al. (2014). Effect of Icodextrin on Heart Rate Variability in Diabetic Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 34(1), 57–63. doi: 10.3747/pdi.2012.00279

Stenvinkel, P., Carrero, J., Axelsson, J., Lindholm, B., Heimbürger, O., & Massy, Z. (2008). Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle. Clinical Journal of the American Society of Nephrology, 3(2), 505–521. doi: 10.2215/CJN.03670807

Brotman, D. J., Bash, L. D., Qayyum, R., Crews, D., Whitsel, E. A., Astor, B. C., & Coresh, J. (2010). Heart Rate Variability Predicts ESRD and CKD-Related Hospitalization. Journal of the American Society of Nephrology : Clinical Journal of the American Society of Nephrology, 21(9), 1560–1570. doi: 10.1681/ASN.2009111112

Chrapko, B., Grzebalska, A., Nocuń, A., Książek, A., & Drop A. (2014). Cardiac sympathetic hyperactivity in chronic kidney disease – a comparison between haemodialysis and peritoneal dialysis patients. Nucl. Med. Rev, 17(2), 75–82. doi: 10.5603/NMR.2014.0021

Demirci, M. S., Demirci, C., Ozdogan, O., Kircelli, F., Akcicek, F., Basci, A., et al. (2011). Relations between malnutrition–inflammation–atherosclerosis and volume status. The usefulness of bioimpedance analysis in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 26(5), 1708–1716. doi: 10.1093/ndt/gfq588

Chandra, P., Sands, R. L., Gillespie, B. W., Levin, N. W., Kotanko, P., Kiser, M., et al. (2012). Predictors of heart rate variability and its prognostic significance in chronic kidney disease. Nephrology Dialysis Transplantation, 27(2), 700–709. doi: 10.1093/ndt/gfr340

Provatopoulou, S. T., & Ziroyiannis, P. N. (2011). Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects. Hippokratia, 15(2), 109–115.

Loboda, O. M., Dudar, I. O., & Gonchar, Y. I. (2017). Varіabelnіst sertsevoho rytmu u khvorykh, yakі lіkuiutsia hemodіalіzom [Heart rate variability in hemodialysis patients]. Ukrainskyi zhurnal nefrolohii ta dializu, 2(38), 93–99. doi: https://doi.org/10.31450/ukrjnd.2(38).2013.07

John, S. G., Selby, N. M., & McIntyre, C. W. (2008). Effects of peritoneal dialysis fluid biocompatibility on baroreflex sensitivity. Kidney Int Suppl., 108, S119–24. doi: 10.1038/sj.ki.5002612 [in Ukrainian].

Roumelioti, M., Ranpuria, R., Hall, M., Hotchkiss, J. R., Chan, C. T., Unruh, M. L., & Argyropoulos, C. (2010). Abnormal nocturnal heart rate variability response among chronic kidney disease and dialysis patients during wakefulness and sleep. Nephrology Dialysis Transplantation, 25(11), 3733–3741. doi: 10.1093/ndt/gfq234

Tang, W., Li, L. X., Pei J., & Wang T. (2012). Heart rate variability in peritoneal dialysis patients: what is the role of residual renal function?. Blood Purif., 34(1), 58–66. doi: 10.1159/000338184

Kida, N., Tsubakihara, Y., Kida, H., Ageta, S., Arai, M., Hamada, Y., & Matsuura, N. (2017). Usefulness of measurement of heart rate variability by holter ECG in hemodialysis patients. BMC Nephrology, 18, 8. doi: 10.1186/s12882-016-0423-3

Loboda, O. M., Dudar, I. O., & Gonchar, Y. I. (2014). Heart rate variability in patients with chronic kidney disease st. III–IV. Sbornik tezisov III Konhressa nefrolohov novykh nezavisimykh gosudarstv (S. 63–65). Tbilisi.

Park, K. W., Kyun Bae, S., Lee, B., Hun Baek, J., Woo Park, J., Jin Moon, S., & Yoon, S. Y. (2013). The effect of on-line hemodiafiltration on heart rate variability in end-stage renal disease. Kidney Research and Clinical Practice, 32(3), 127–133. doi: 10.1016/j.krcp.2013.06.002

Ferrario, M., Moissl, U., Garzotto, F., Cruz, D. N., Clementi, A., Brendolan, A., et al. (2014). Effects of fluid overload on heart rate variability in chronic kidney disease patients on hemodialysis. BMC Nephrology, 15, 26. http://doi.org/10.1186/1471-2369-15-26

Lutfi, M. F. (2011). Effects of Hemoglobin Concentration on Heart Rate Variability International Journal of Pharmaceutical and Biological Research, 2(5), 127–131.

Kolesnyk, M. O., Dudar, I. O., Stepanova, N. M., Honchar, Yu. I., Shifris, I. M., & Loboda, O. M. (2016). Likuvannia khvorykh na khronichnu khvorobu nyrok V HD stadii. Adaptovana klinichna nastanova, zasnovana na dokazakh ta unifikovani klinichni protokoly [Treatment of patients with chronic kidney disease V stage. Adapted clinical guideline based on evidence and unified clinical protocols]. Kyiv: Polihraf plius. [in Ukrainian].

Brunelli, S. M., Monda, K. L., Burkart, J. M., Gitlin, M., Neumann, P. J., Park, G. S., et al. (2013). Early Trends From the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS). American Journal of Kidney Diseases, 61(6), 947–956. doi: 10.1053/j.ajkd.2012.11.040

Rebrova, O. Yu. (2003). Statisticheskij analiz medicinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA [Statistical analysis of medical data. Application of the STATISTICA software package]. Moscow: Mediasfera. [in Russian].

Halliwell, J. R., & Minson, C. T. (2002). Effect of hypoxia on arterial baroreflex control of heart rate and muscle sympathetic nerve activity in humans. Appl Physiol, 93, 857–864. doi: 10.1152/japplphysiol.01103.2001

Bartnicki, P., Rysz, J., Franczyk, B., Baj, Z., & Majewska, E. (2016). Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease. Oxidative Medicine and Cellular Longevity, 2016(4), 1–9. doi: 10.1155/2016/9879615

Nishizawa, K., Yano, T., Tanno, M., Miki, T., Kuno, A., Tobisawa, T., et al. (2016). Chronic Treatment With an Erythropoietin Receptor LigandPrevents Chronic Kidney Disease–Induced Enlargementof Myocardial Infarct Size. Hypertension, 68(3), 697–706. doi: 10.1161/HYPERTENSIONAHA.116.07480

Maduell, F., Moreso, F., Pons, M., Ramos, R., Mora-Macià, J., Carreras, J., et al. (2013). High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis Patients. Journal of the American Society of Nephrology, 24(3), 487–97. doi: 10.1681/ASN.2012080875

Martinez-Vea, A., Marcas, L., Bardají, A., Romeu, M., Gutierrez, C., García, C., et al. (2012). Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease. Clinical Nephrology, 77(3), 171–181. doi: 10.5414/CN107309

Schmid, H., Schiffl, H., & Lederer, S. R. (2011). Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient. Current Opinion in Nephrology and Hypertension, 20(5), 465–470. doi: 10.1097/MNH.0b013e3283497057

Foley, R. N., Parfrey, P. S., Morgan, J., Barré, P. E., Campbell, P., Cartier, P., et al. (2000). Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney International, 58(3), 1325–1335. doi: 10.1046/j.1523-1755.2000.00289.x

Locatelli, F., Del Vecchio, L., & Pozzoni, P. (2006). Anemia and cardiovascular risk: the lesson of the CREATE Trial. J Am Soc Nephrol, 17(12 Suppl 3), S262-6. doi: 10.1681/ASN.2006080924

Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006). Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. Engl J Med, 355(20), 2085–2098. doi: 10.1056/NEJMoa065485

Mix, T. C., Brenner, R. M., Cooper, M. E., de Zeeuw, D., Ivanovich, P., Levey, A. S., et al. (2005). Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J, 149(3), 408–13. doi: 10.1016/j.ahj.2004.09.047

Drüeke, T., Locatelli, F., Clyne, N., Eckardt, K-U., Macdougall, L. C., Tsakiris, D., et al. (2006). Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The New England Journal of Medicine, 355(20), 2071–2084. doi: 10.1056/NEJMoa062276

Timmer, S., Boer, K., Knaapen, P., Götte, M., & Rossum, V. (2009). The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? Journal of Cardiac Failure, 15(4), 353–61. doi: 10.1016/j.cardfail.2008.10.024

Frank, H., Heusser, K., Höffken, B., Huber, P., Schmieder, R. E., & Schobel, H. P. (2004). Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney International, 66(2), 832–840. doi: 10.1111/j.1523-1755.2004.00810.x

Pacyk, G. L., & Grzeszczak, W. (1997). The effect of recombinant human erythropoietin (rHu-EPO) on the autonomic nervous system in patients hemodialyzed for chronic kidney failure. Pol Arch Med Wewn, 97(1), 22–29.

Pfeffer, M. A., Burdmann, E. A., Chen, C-Y., Cooper, M. T., Zeeuw, D., Eckardt, K. U., et al. (2009). A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England Journal of Medicine, 361(21), 2019–2032. doi: 10.1056/NEJMoa0907845

Stojcheva-Taneva, O. O., & Polenakovic, M. H. (1996). Autonomic neuropathy in hemodialysis patients treated with recombinant human erythropoietin. Int J Artif Organs, 19(10), 574–577.

Battipaglia, I., Scalone, G., Macchione, A., Pinnacchio, G., Laurito, M., Milo, M., et al. (2012). Association of heart rate variability with arrhythmic events in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation Journal, 76(3), 618–623.

Pei, J., Tang, W., Li, L-X., Su, C-Y., & Wang T. (2012). The Study of Spectral Analysis of Heart Rate Variability in Different Blood Pressure Types in Euvolemic Peritoneal Dialysis Patients. Renal Failure, 34(6), 722–726. doi: 10.3109/0886022X.2012.681589

Downloads

How to Cite

1.
Stepanova NM, Kolesnyk MO, Novakivskyi VV, Loboda OM, Snisar LM, Shifris IM. Dose-dependent effect of continuous erythropoietin receptor activator on cardiac autonomic nervous activity and cardiovascular events in patients treated with online hemodiafiltration. Zaporozhye Medical Journal [Internet]. 2019May31 [cited 2024Nov.23];(3). Available from: http://zmj.zsmu.edu.ua/article/view/169112

Issue

No. 3 (2019)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)